Eniluracil is a small molecule commercialized by Processa Pharmaceuticals, with a leading Phase III program in Metastatic Colorectal Cancer. According to Globaldata, it is involved in 22 clinical trials, of which 17 were completed, 2 are ongoing, 1 is planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Eniluracil’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Eniluracil is expected to reach an annual total of $15 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Eniluracil Overview

Eniluracil is under development for the treatment of metastatic breast cancer, metastatic colorectal cancer and pancreatic cancer. The drug candidate is administered through oral route. It targets dihydropyrimidine dehydrogenase. It was also under development for hepatocellular carcinoma , non-small cell lung carcinoma, gastric cancer, cervical cancer, prostate cancer.

Processa Pharmaceuticals Overview

Processa Pharmaceuticals, formerly Heatwurx, is a biopharmaceutical company which develops and commercializes drugs for the treatment of skin diseases and various cancer types. It is investigating its lead product candidate: PCS499 to treat necrobiosis lipoidica (NL), a chronic, disfiguring skin disorder; and to treat the side effects of radiation in patients with head and neck cancer. The PCS499 holds Orphan Drug designation for the treatment of NL. The company is evaluating PCS100, an anti-fibrotic and anti-inflammatory drug against idiopathic pulmonary fibrosis (IPF) and primary glomerulonephritis. It operates in the US. Processa Pharmaceuticals is headquartered in Baltimore, Maryland, the US.

The operating loss of the company was US$12 million in FY2021, compared to an operating loss of US$15.1 million in FY2020. The net loss of the company was US$11.4 million in FY2021, compared to a net loss of US$14.4 million in FY2020.

For a complete picture of Eniluracil’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.